Parotid acinic cell cancer is considered a very rare yet treatable disease. This type of cancer only accounts for roughly 10% of all salivary gland tumors.
Beverly Hills, CA (PRWEB) May 21, 2013
Babak Larian, MD, FACS, in Beverly Hills agrees with the latest study regarding radiotherapy and it’s uses in the treatment of early stage parotid acinic cell cancer. According to the study, adjuvant radiotherapy does not provide a therapeutic advantage in patients experiencing early stage parotid acinic cell carcinoma. The benefit of radiotherapy for patients managing a higher stage disease has yet to be determined. This particular study gathered information that included all 1,241 patients who had been diagnosed with the disease over the course of the past twenty years.
“Parotid acinic cell cancer is considered a very rare yet treatable disease. This type of cancer only accounts for roughly 10% of all salivary gland tumors,” said Dr. Larian, Otolaryngologist in Beverly Hills.
Acinic cell carcinoma commonly appears as a tumor that is most frequently found in the parotid gland. This particular form of cancer presents patients with a relatively high survival rate when treated in a timely manor, with a five-year survival rate near 90% and a twenty-year survival rate over 50%. At the Center for Advanced Parotid Surgery in Beverly Hills, Dr. Larian performs and his team of experts perform several different procedures for patients experiencing acinic cell carcinoma of the parotid gland, including submandibular gland resection and a minimally invasive procedure known as a micro parotidectomy.
“Though radiotherapy may not be the best treatment for patients experiencing early-stage parotid aciniccell cancer, there are several other treatment options that work extremely well. At the Center for Advanced Head & Neck Surgery, we have pioneered the micro parotidectomy, a minimally invasive surgical procedure responsible for the removal of a patients infected parotid gland,” said Dr. Larian.
Despite the studies findings regarding the treatment for early stage parotid acinic cell cancer using radiotherapy, results concerning its use in late-stage patients remains unresolved.
Dr. Babak Larian is a graduated with distinction from UC Irvine School of Medicine and has completed a six-year residency program in Otalryngology and Head & Neck Surgery at UCLA. As the Chairman and Director of the Center for Advanced Parotid Surgery in Los Angeles, Dr. Larian is responsible for the performance of surgeries on parotid and salivary glands. Dr. Larian aims to provide his patients with the best possible care and surgical outcomes 100% of the time.
For more information about Dr. Larian and the Center for Advanced Head & Neck Surgery, please contact his office today by calling (310) 461-0300 or visit him on the web at: http://www.parotidmd.com